Heptares Therapeutics extends multi-fte chemistry collaboration with Oxygen Healthcare

21-May-2010 - United Kingdom

Executives from Heptares Therapeutics and O2h announced an extension of the agreement under which O2h provides multi-FTE -synthetic chemistry services to support discovery programmes at Heptares.

Dr. Miles Congreve, Head of Chemistry said, “We are happy to have signed this new contract with O2h; they have been a solid chemistry partner and have also supported us with some basic ADME, which helps to reduce discovery cycle times.”

Sunil Shah, CEO, O2h “We have had a successful partnership with Heptares Therapeutics and are delighted at this extension for the third year. Heptares has a very innovative technology that we are happy to have supported since inception and believe will lead to new GPCR drugs being discovered.”

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances